ATT-LD is a pro-drug of levodopa for the treatment of Parkinson’s disease. Levodopa was introduced in 1968 and since then has been used successfully as the drug of choice for the symptomatic treatment of Parkinson's disease. Levodopa is very effective following its initiation, however, after chronic levodopa use, treatment is accompanied by severe side-effects such as motor fluctuations and dyskinesias (abnormal movements) among other complications of therapy.

The side effects of levodopa in late stage Parkinson’s patients are due to the depletion of the intrinsic dopamine storage terminals in the brain which causes fluctuations in Levodopa plasma concentrations, and relate to the short half-life of the drug upon administration (about 30 minutes).

ATT-LD is developed as a long-acting pro-drug of levodopa that, upon oral administration, accumulates and gradually releases levodopa into the blood, maintaining a fairly constant blood level of the drug which will decrease side effects.

ATT-LD is in lead selection stage and pre-clinical studies demonstrated continuous generation of levodopa for up to 6 hrs in rat plasma upon single oral administration with Steady and extended formation of Levodopa upon oral delivery of ATT-LD pro-drug